News
Sandoz already markets a short-acting GCSF biosimilar branded as Zarxio, a near-copy of Amgen’s originator drug, Neupogen (filgrastim). Amgen’s US patent on Neulasta expired in October 2015 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback